Novavax: The Beaten-Down COVID-19 Darling

Impact · against what's priced in

Novavax appears undervalued as the market focuses on declining Nuvaxovid sales rather than the structural value of its Matrix-M adjuvant partnerships. While the revenue shift creates concentration risk, the validation from Pfizer and Sanofi provides a floor that the current enterprise value of $716 million likely underestimates.

NVAX+0.40

No priced-in read yet

In context

The shift from product sales to a licensing model centered on Matrix-M partnerships with Sanofi and Pfizer creates a high-value floor not fully reflected in the $716 million enterprise value.

Read from the article alone

• royalties▲400%
• pharmaceuticals▲5%
• biotech▲3%
• valuation
• NVAX
• PFE
• SNY